UBS Group AG Sells 62,771 Shares of QuidelOrtho Corporation $QDEL

UBS Group AG lowered its stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 11.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 476,617 shares of the company’s stock after selling 62,771 shares during the quarter. UBS Group AG’s holdings in QuidelOrtho were worth $13,612,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allianz Asset Management GmbH increased its position in QuidelOrtho by 98.6% during the third quarter. Allianz Asset Management GmbH now owns 463,223 shares of the company’s stock worth $13,642,000 after acquiring an additional 229,938 shares during the period. Ballast Asset Management LP increased its stake in QuidelOrtho by 217.7% during the third quarter. Ballast Asset Management LP now owns 80,019 shares of the company’s stock valued at $2,357,000 after acquiring an additional 54,829 shares during the period. Aristotle Capital Boston LLC increased its stake in QuidelOrtho by 62.4% during the third quarter. Aristotle Capital Boston LLC now owns 382,389 shares of the company’s stock valued at $11,261,000 after acquiring an additional 146,956 shares during the period. American Century Companies Inc. increased its stake in QuidelOrtho by 10.4% during the third quarter. American Century Companies Inc. now owns 2,115,557 shares of the company’s stock valued at $62,303,000 after acquiring an additional 199,909 shares during the period. Finally, Gagnon Securities LLC increased its stake in QuidelOrtho by 68.1% during the third quarter. Gagnon Securities LLC now owns 122,499 shares of the company’s stock valued at $3,608,000 after acquiring an additional 49,622 shares during the period. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Trading Up 3.1%

QDEL stock opened at $11.39 on Friday. QuidelOrtho Corporation has a 1-year low of $9.92 and a 1-year high of $35.58. The firm has a market cap of $776.68 million, a P/E ratio of -0.64 and a beta of 0.75. The business’s 50 day moving average is $14.98 and its 200-day moving average is $22.91. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The company had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same quarter in the prior year, the company posted $0.74 earnings per share. The company’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities analysts anticipate that QuidelOrtho Corporation will post 1.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Citigroup lowered their price target on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Sunday, April 12th. UBS Group reissued a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and lowered their price target for the company from $35.00 to $12.50 in a report on Thursday, May 7th. Three analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $14.88.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.